Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Other

Effect of photobiomodulation in the balance between effector and regulatory T cells in an experimental model of COPD

This study suggests that PBM treatment could be applied as an immunotherapeutic strategy for COPD.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

In this mouse study, COPD was induced with cigarette smoke extract and animals received photobiomodulation for seven weeks. The authors report that treatment was associated with fewer inflammatory cells, lower IFN-γ, less collagen and alveolar enlargement, and higher IL-10 and regulatory T cell levels. They suggest photobiomodulation could be considered as an immunotherapeutic strategy for COPD.

Who or what was studied
C57BL/6 mice with experimentally induced COPD
Limits stated in the abstract
This is an animal study, and the abstract does not report the number of animals or the light parameters used.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Introduction

Currently, Chronic Obstructive Pulmonary Disease (COPD) has a high impact on morbidity and mortality worldwide. The increase of CD4+, CD8+ cells expressing NF-κB, STAT4, IFN-γ and perforin are related to smoking habit, smoking history, airflow rate, obstruction and pulmonary emphysema. Furthermore, a deficiency in CD4+CD25+Foxp3+ regulatory T cells (Tregs) may impair the normal function of the immune system and lead to respiratory immune disease. On the other hand, the anti-inflammatory cytokine IL-10, produced by Treg cells and macrophages, inhibits the synthesis of several pro-inflammatory cytokines that are expressed in COPD. Therefore, immunotherapeutic strategies, such as Photobiomodulation (PBM), aim to regulate the levels of cytokines, chemokines and transcription factors in COPD. Consequently, the objective of this study was to evaluate CD4+STAT4 and CD4+CD25+Foxp3+ cells as well as the production of CD4+IFN- γ and CD4+CD25+IL-10 in the lung after PBM therapy in a COPD mice model.

Methods

We induced COPD in C57BL/6 mice through an orotracheal application of cigarette smoke extract. PMB treatment was applied for the entire 7 weeks and Bronchoalveolar lavage (BAL) and lungs were collected to study production of IFN- γ and IL-10 in the lung. After the last administration with cigarette smoke extract (end of 7 weeks), 24 h later, the animals were euthanized. One-way ANOVA followed by NewmanKeuls test were used for statistical analysis with significance levels adjusted to 5% (p < 0.05).

Results

This result showed that PBM improves COPD symptomatology, reducing the number of inflammatory cells (macrophages, neutrophils and lymphocytes), the levels of IFN-γ among others, and increased IL-10. We also observed a decrease of collagen, mucus, bronchoconstriction index, alveolar enlargement, CD4+, CD8+, CD4+STAT4+, and CD4+IFN-γ+ cells. In addition, in the treated group, we found an increase in CD4+CD25+Foxp3+ and CD4+IL-10+ T cells.

Conclusion

This study suggests that PBM treatment could be applied as an immunotherapeutic strategy for COPD.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation, Collagen. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies